These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26063766)

  • 1. Inhibition of Glucosylceramide Synthase Sensitizes Head and Neck Cancer to Cisplatin.
    Roh JL; Kim EH; Park JY; Kim JW
    Mol Cancer Ther; 2015 Aug; 14(8):1907-15. PubMed ID: 26063766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting acid ceramidase sensitises head and neck cancer to cisplatin.
    Roh JL; Park JY; Kim EH; Jang HJ
    Eur J Cancer; 2016 Jan; 52():163-72. PubMed ID: 26687835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition.
    Kim EH; Jang H; Roh JL
    Mol Cancer Ther; 2016 Nov; 15(11):2620-2629. PubMed ID: 27550943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.
    Roh JL; Park JY; Kim EH; Jang HJ; Kwon M
    Cancer Lett; 2016 Feb; 371(1):20-9. PubMed ID: 26607904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
    Roh JL; Kim EH; Jang HJ; Park JY; Shin D
    Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
    Tyler A; Johansson A; Karlsson T; Gudey SK; Brännström T; Grankvist K; Behnam-Motlagh P
    Exp Cell Res; 2015 Aug; 336(1):23-32. PubMed ID: 26004871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer.
    Kim EH; Jang H; Shin D; Baek SH; Roh JL
    Apoptosis; 2016 Nov; 21(11):1265-1278. PubMed ID: 27544755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
    Roh JL; Kim EH; Jang H; Shin D
    Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
    Shin D; Kim EH; Lee J; Roh JL
    Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hederagenin Induces Apoptosis in Cisplatin-Resistant Head and Neck Cancer Cells by Inhibiting the Nrf2-ARE Antioxidant Pathway.
    Kim EH; Baek S; Shin D; Lee J; Roh JL
    Oxid Med Cell Longev; 2017; 2017():5498908. PubMed ID: 29456786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer.
    Roh JL; Park JY; Kim EH
    Apoptosis; 2014 Nov; 19(11):1594-602. PubMed ID: 25113507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
    Shin D; Kim EH; Lee J; Roh JL
    Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition.
    Roh JL; Kim EH; Jang H; Shin D
    Free Radic Biol Med; 2017 Mar; 104():1-9. PubMed ID: 28057599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GCS overexpression is associated with multidrug resistance of human HCT-8 colon cancer cells.
    Song M; Zang W; Zhang B; Cao J; Yang G
    J Exp Clin Cancer Res; 2012 Mar; 31(1):23. PubMed ID: 22424291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceramide glycosylation potentiates cellular multidrug resistance.
    Liu YY; Han TY; Giuliano AE; Cabot MC
    FASEB J; 2001 Mar; 15(3):719-30. PubMed ID: 11259390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.
    Liu YY; Gupta V; Patwardhan GA; Bhinge K; Zhao Y; Bao J; Mehendale H; Cabot MC; Li YT; Jazwinski SM
    Mol Cancer; 2010 Jun; 9():145. PubMed ID: 20540746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P-Glycoprotein Overexpression Is Associated With Cisplatin Resistance in Human Osteosarcoma.
    He C; Sun Z; Hoffman RM; Yang Z; Jiang Y; Wang L; Hao Y
    Anticancer Res; 2019 Apr; 39(4):1711-1718. PubMed ID: 30952710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer.
    Roh JL; Kim EH; Park JY; Kim JW; Kwon M; Lee BH
    Oncotarget; 2014 Oct; 5(19):9227-38. PubMed ID: 25193861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
    Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
    Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma.
    Stefanovic M; Tutusaus A; Martinez-Nieto GA; Bárcena C; de Gregorio E; Moutinho C; Barbero-Camps E; Villanueva A; Colell A; Marí M; García-Ruiz C; Fernandez-Checa JC; Morales A
    Oncotarget; 2016 Feb; 7(7):8253-67. PubMed ID: 26811497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.